Our results also indicate that, in addition to HMGCR, the targeting of other enzymes of the mevalonate pathway (e.g., HMGCS1) could be an option for impairing the fitness of breast cancer tumors through the reduction of neoangiogenesis and the increase in basal rates of cancer cell apoptosis within the tumor mass. This evidence concerns the gene HMGCS1 and cancer.